Robert J. Fram

2.2k total citations
82 papers, 1.6k citations indexed

About

Robert J. Fram is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Robert J. Fram has authored 82 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 41 papers in Oncology and 21 papers in Hematology. Recurrent topics in Robert J. Fram's work include Acute Myeloid Leukemia Research (17 papers), Cancer therapeutics and mechanisms (13 papers) and Lung Cancer Treatments and Mutations (11 papers). Robert J. Fram is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Cancer therapeutics and mechanisms (13 papers) and Lung Cancer Treatments and Mutations (11 papers). Robert J. Fram collaborates with scholars based in United States, France and Japan. Robert J. Fram's co-authors include Donald Küfe, D Kufe, John M. Wilson, Martin Marinus, Douglas V. Faller, Edward A. Sausville, David A. Van Echo, George Dover, Nancy Tait and David Rosen and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Robert J. Fram

77 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert J. Fram United States 25 903 598 292 177 130 82 1.6k
Hitomi Yamamoto Japan 20 675 0.7× 506 0.8× 226 0.8× 213 1.2× 90 0.7× 40 1.7k
Anna Scuto United States 19 1.4k 1.6× 667 1.1× 301 1.0× 278 1.6× 257 2.0× 30 2.2k
W. Jens Zeller Germany 22 1.0k 1.1× 635 1.1× 204 0.7× 115 0.6× 91 0.7× 123 1.8k
Xiuli Wu China 24 1.0k 1.1× 718 1.2× 416 1.4× 239 1.4× 92 0.7× 145 2.4k
Masaki Ri Japan 24 1000 1.1× 576 1.0× 461 1.6× 119 0.7× 200 1.5× 117 1.9k
Ruoping Tang France 24 675 0.7× 729 1.2× 340 1.2× 173 1.0× 234 1.8× 40 1.7k
G Schwab United States 16 988 1.1× 1.0k 1.7× 566 1.9× 135 0.8× 118 0.9× 23 2.3k
Eric Scholar United States 18 893 1.0× 581 1.0× 141 0.5× 162 0.9× 131 1.0× 27 1.8k
Nandini Kishore United States 15 451 0.5× 601 1.0× 258 0.9× 356 2.0× 110 0.8× 20 1.9k
James R. Zucali United States 19 593 0.7× 470 0.8× 259 0.9× 263 1.5× 60 0.5× 42 1.5k

Countries citing papers authored by Robert J. Fram

Since Specialization
Citations

This map shows the geographic impact of Robert J. Fram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Fram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Fram more than expected).

Fields of papers citing papers by Robert J. Fram

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Fram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Fram. The network helps show where Robert J. Fram may publish in the future.

Co-authorship network of co-authors of Robert J. Fram

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Fram. A scholar is included among the top collaborators of Robert J. Fram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Fram. Robert J. Fram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stewart, G., et al.. (2025). 88P: Real-world occurrence of early-onset pulmonary events with brigatinib for advanced ALK+ NSCLC. Journal of Thoracic Oncology. 20(3). S64–S65.
2.
Jänne, Pasi A., Bin-Chao Wang, Byoung Chul Cho, et al.. (2025). First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology. 43(13). 1553–1563. 7 indexed citations
3.
4.
5.
Regnault, Antoine, Farrah Pompilus, Rafael Bejar, et al.. (2021). Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30. Journal of Patient-Reported Outcomes. 5(1). 60–60. 8 indexed citations
6.
Fram, Kamil, et al.. (2020). Approach of gynecological cancers at Jordan UniversityHospital: facts and figures. European Journal of Gynaecological Oncology. 41(1). 89–89. 2 indexed citations
7.
Bell, Jill A., Aaron Galaznik, Farrah Pompilus, et al.. (2019). A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Patient-Reported Outcomes. 3(1). 35–35. 10 indexed citations
8.
Bell, Jill A., Aaron Galaznik, Marlo Blazer, et al.. (2018). Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. PharmacoEconomics - Open. 3(2). 237–245. 14 indexed citations
9.
Bell, Jill A., et al.. (2018). Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 18(4). e157–e166. 11 indexed citations
10.
11.
Cutsem, Eric Van, Robert J. Fram, Michael Schlichting, & David P. Ryan. (2013). Phase 3 Trial of Gemcitabine and Th-302 Compared with Gemcitabine and Placebo in Patients with Pancreatic Adenocarcinoma: the Maestro Trial. Annals of Oncology. 24. iv85–iv85. 2 indexed citations
12.
Yin, Mao, et al.. (2009). Abstract #1572: Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat. Cancer Research. 69. 1572–1572. 1 indexed citations
13.
Ishitsuka, Kenji, Teru Hideshima, Makoto Hamasaki, et al.. (2005). Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 24(38). 5888–5896. 57 indexed citations
14.
Villalona‐Calero, Miguel A., Sharyn D. Baker, L. A. Hammond, et al.. (1998). Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.. Journal of Clinical Oncology. 16(8). 2770–2779. 24 indexed citations
15.
Glover, Donna, et al.. (1994). Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer. 74(11). 2949–2955. 85 indexed citations
16.
Fram, Robert J., et al.. (1990). Mechanisms underlying resistance to streptozotocin in Mer+ and Mer− human tumor lines. Biochemical Pharmacology. 39(5). 959–964. 1 indexed citations
17.
Fram, Robert J., et al.. (1989). DNA repair mechanisms affecting cytotoxicity by streptozotocin in E. coli. Mutation Research/DNA Repair. 218(2). 125–133. 10 indexed citations
18.
Fram, Robert J., et al.. (1988). Gene expression in E. coli after treatment with streptozotocin. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 198(1). 45–51. 8 indexed citations
19.
Fram, Robert J., et al.. (1988). Sequence specificity of streptozotocin-induced mutations. Nucleic Acids Research. 16(20). 9811–9820. 3 indexed citations
20.
Fram, Robert J.. (1986). A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation. Cell Biology and Toxicology. 2(4). 531–539. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hitomi Yamamoto Breakdown of academic impact, for papers by Anna Scuto Breakdown of academic impact, for papers by W. Jens Zeller Breakdown of academic impact, for papers by Xiuli Wu Breakdown of academic impact, for papers by Masaki Ri Breakdown of academic impact, for papers by Ruoping Tang Breakdown of academic impact, for papers by G Schwab Breakdown of academic impact, for papers by Eric Scholar Breakdown of academic impact, for papers by Nandini Kishore Breakdown of academic impact, for papers by James R. Zucali
Rankless by CCL
2026